Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10412
Title: Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy.
Austin Authors: Berkovic, Samuel F ;Knowlton, R C;Leroy, R F;Schiemann, J;Falter, U
Institutional Author: Levetiracetam N01057 Study Group
Affiliation: Epilepsy Research Center, Heidelberg Repatriation Hospital, Banksia Street, West Heidelberg, Victoria, Australia
Issue Date: 11-Jul-2007
Publication information: Neurology 2007; 69(18): 1751-60
Abstract: To assess the efficacy and tolerability of adjunctive levetiracetam in patients with uncontrolled generalized tonic-clonic (GTC) seizures associated with idiopathic generalized epilepsies (IGE).This multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled adults and children (4 to 65 years) with IGE experiencing >or=3 GTC seizures during the 8-week baseline period (4-week retrospective and 4-week prospective), despite receiving stable doses of one or two antiepileptic drugs (AEDs). Patients were randomized to levetiracetam (target dose 3,000 mg/day for adults; 60 mg/kg/day for children) or placebo and a 4-week titration period was followed by a 20-week evaluation period.Of 229 patients screened, 164 were randomized (levetiracetam, n = 80; placebo, n = 84). Levetiracetam produced a greater mean reduction in GTC seizure frequency per week over the treatment period (56.5%) than placebo (28.2%; p = 0.004). The percentage of patients who had >or=50% reduction of GTC seizure frequency per week (responders) during the treatment period was 72.2% for levetiracetam and 45.2% for placebo (p < 0.001; OR 3.28; 95% CI 1.68 to 6.38). During the first 2-week treatment 64.6% of patients on levetiracetam and 45.2% on placebo (p = 0.018) were classified as responders. During the evaluation period the percent of patients free of GTC seizures (34.2% vs 10.7%; p < 0.001) and all seizure types (24.1% vs 8.3%; p = 0.009) was greater for levetiracetam than placebo. Levetiracetam was well tolerated with 1.3% of patients discontinuing therapy due to adverse events vs 4.8% on placebo.Adjunctive levetiracetam is an effective and well-tolerated antiepileptic drug for treating generalized tonic-clonic seizures in patients with idiopathic generalized epilepsies.
Gov't Doc #: 17625106
URI: http://ahro.austin.org.au/austinjspui/handle/1/10412
DOI: 10.1212/01.wnl.0000268699.34614.d3
URL: https://pubmed.ncbi.nlm.nih.gov/17625106
Type: Journal Article
Subjects: Adolescent
Adult
Aged
Anticonvulsants.therapeutic use
Child
Child, Preschool
Double-Blind Method
Epilepsy, Generalized.drug therapy
Female
Humans
Male
Middle Aged
Piracetam.analogs & derivatives.therapeutic use
Placebos
Quality of Life
Questionnaires
Research Design
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Nov 28, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.